Skip to content
Blackberry Empire – Lifestyle
Author:
SynAct Pharma
WHO Identifies Resomelagon as One Of Six Dengue Drug Candidates with Evidence Supporting Further Clinical Development
September 16, 2026
Further Analysis of the Phase 2b ADVANCE Study Reinforces Phase 2b EXPAND Results and Supports Phase 3 Development – FDA Discussions on Trial Design Planned for Q4 2026
September 7, 2026
SynAct Pharma’s CEO and CSO Sell Shares
September 3, 2026